Last reviewed · How we verify
Mebendazole + Multivitamin
Mebendazole disrupts microtubule formation in parasitic worms, causing paralysis and death, while the multivitamin component addresses nutritional deficiencies often associated with helminthic infections.
Mebendazole disrupts microtubule formation in parasitic worms, causing paralysis and death, while the multivitamin component addresses nutritional deficiencies often associated with helminthic infections. Used for Soil-transmitted helminth infections (roundworm, hookworm, whipworm) in children in endemic regions, Nutritional support in populations with high parasitic infection burden.
At a glance
| Generic name | Mebendazole + Multivitamin |
|---|---|
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Drug class | Anthelmintic + nutritional supplement |
| Target | β-tubulin (mebendazole component) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Mebendazole is a benzimidazole anthelmintic that binds to β-tubulin and inhibits microtubule polymerization in nematodes and other helminths, leading to immobilization and eventual death of the parasites. The addition of multivitamin supplementation addresses micronutrient deficiencies (iron, vitamin A, B vitamins, etc.) that commonly occur in populations with parasitic infections, improving overall health outcomes and potentially enhancing immune response.
Approved indications
- Soil-transmitted helminth infections (roundworm, hookworm, whipworm) in children in endemic regions
- Nutritional support in populations with high parasitic infection burden
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Headache
Key clinical trials
- Treatment and Prevention of Severe Anemia in Pregnant Zanzibari Women (PHASE3)
- Severe Anemia Treatment Trials, Pakistan (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: